FDA Approves H5N1 Avian Influenza Vaccine
MONDAY, Nov. 25, 2013 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first adjuvanted vaccine for the prevention of H5N1 influenza in adults at greater-than-average risk of exposure.
While most strains of avian influenza don't infect people, the H5N1 virus has caused "serious illness and death in people outside of the United States, mostly among people who have been in close contact with infected and ill poultry," the agency said in a news release announcing the approval.
The shot, called the Influenza A (H5N1) Virus Monovalent Vaccine, has been developed "in the event that the H5N1 avian influenza virus develops the capability to spread efficiently from human to human, resulting in the rapid spread of the disease across the globe," the FDA added.
The vaccine, produced by a Canadian subsidiary of GlaxoSmithKline, is not intended for commercial distribution, the FDA said. It's designed to be administered in two doses given three weeks apart.
In clinical testing involving some 3,400 adults, the most common side effects included injection-site pain and swelling, muscle aches, headache, and fatigue.
Related Articles
Search Allergy Articles
Black, Hispanic Patients With Severe Allergies Less Likely to Get Allergy Shots
Stay Independent of Allergies, Asthma This July Fourth
FDA Panel Recommends Approval of First Nasal Spray to Combat Severe Allergy Attacks
Seniors, Here Are the Meds That Can Harm Your Driving Skills
For Kids in Poorer Neighborhoods, a Move Can Ease Asthma
American Lung Association Blasts Biden for Inaction on Menthol Cigarette Ban
Could Inhaling a Statin Help Ease Asthma, COPD?
Nova Scotia Wildfires Sending Unhealthy 'Smoke Plume' to U.S. Northeast
Healthy, Diverse Infant Microbiome Could Shield Kids From Asthma